drugset / Trial / NCT00581100

Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

NCT00581100

Phase 4 Completed 136 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.

Timeline

Start
2007-09
Primary completion
2009-08
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications